A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized high-risk participants with COVID-19
The SCORPIO-HR Study is a clinical research study looking at an investigational drug for COVID-19 in people who have tested positive and whether it can help resolve COVID-19 symptoms faster and reduce COVID-19 symptoms that persist for several months (called “long COVID”).
Participation in the study will last about 24 weeks and participants will have at least 8 study visits. Participants will be randomly assigned to take the investigational drug or a placebo as 3 tablets on the first day of study treatment followed by 1 tablet a day for 4 days.
MoreAdult
You, or someone you know, may be able to take part if you/they: -are 18 years of age or older -have had a positive diagnosis of COVID-19 within the past 72 hours (3 days) -are experiencing COVID-19 symptoms such as coughing, shortness of breath, feeling feverish, fatigue, nausea, chills, headaches, or sore throat, among others, within the past 3 days (with one or more symptoms ongoing).
Treatment
National
COMPENSATION PROVIDED
Thomas Campbell, MD
Protocol Number: 22-0587
More information available at ClinicalTrials.gov: NCT05305547
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers